UroGen Pharma has FDA clearance for UGN-501, but can an oncolytic virus work in bladder cancer?
Find out how UroGen Pharma’s UGN-501 could test oncolytic virus therapy for recurrent non-muscle invasive bladder cancer.
Pharma & Biotech
Pharma & Biotech
Could Arcutis Biotherapeutics unlock the next big pediatric dermatology gap with Zoryve?
Arcutis Biotherapeutics has secured U.S. Food and Drug Administration acceptance of its supplemental New Drug Application for Zoryve roflumilast cream 0.05 percent to expand treatment of mild to moderate atopic dermatitis to infants aged 3 to 24 months. The filing moves the steroid-free topical therapy into a regulatory review with a target action date of
Pharma & Biotech
Gain Therapeutics has FDA clearance for GT-02287, but can biomarkers become real benefit?
Find out how Gain Therapeutics’ GT-02287 could test GCase restoration as a disease-modifying strategy for Parkinson’s disease.
Pharma & Biotech
Vera Therapeutics has FDA approval for TRUTAKNA, but the real test comes next
Find out how Vera Therapeutics’ TRUTAKNA approval could reshape IgA nephropathy treatment while key kidney data remain ahead.
Pharma & Biotech
XIAFLEX hit its Phase 3 goals, but can Keenova change plantar fibromatosis care?
Find out how Keenova’s XIAFLEX Phase 3 success could create the first approved drug for plantar fibromatosis.
Pharma & Biotech
Insilico Medicine’s AI-originated IPF drug enters Phase 3, but the hardest test begins now
Find out how Insilico Medicine’s AI-originated rentosertib is entering Phase 3 testing for idiopathic pulmonary fibrosis.
Pharma & Biotech
Pharvaris has an FDA review date for deucrictibant, but can it stand out?
Find out how Pharvaris’ deucrictibant could reshape oral treatment options for hereditary angioedema attacks.
Pharma & Biotech
Can CoRegen’s CRG-150 turn regulatory T cells into a solid tumour weapon?
Find out how CoRegen is advancing CRG-150 into human trials for metastatic breast cancer, prostate cancer and solid tumours.
Pharma & Biotech
LTZ Therapeutics secures FDA clearance for LTZ-232 Phase 1 cancer trial
Find out how LTZ Therapeutics is advancing LTZ-232 into a Phase 1 trial targeting macrophages in metastatic colorectal cancer.
Pharma & Biotech
Kailera advances oral GLP-1 strategy after positive obesity and diabetes Phase 3 trials
Kailera Therapeutics has reported positive Phase 3 results for oral GLP-1 candidate KAI-7535 in obesity and type 2 diabetes, although high gastrointestinal event rates remain a major commercial and clinical concern.